Thomas Agoritsas1, Marie Deom, Thomas V Perneger. 1. Division of Clinical Epidemiology, University Hospitals of Geneva, Gabrielle Perret-Gentil 6, 1211 Geneva 14, Switzerland. thomas.agoritsas@hcuge.ch
Abstract
OBJECTIVE: To identify characteristics of clinical research projects that influence patients' willingness to participate in research. STUDY DESIGN AND SETTING: We surveyed all patients discharged during 1 month from a Swiss public teaching hospital. We described four hypothetical studies and asked patients whether they would agree to participate. We randomly manipulated three study attributes in each vignette, using a factorial design. RESULTS: All studies were not equally acceptable to the 1,277 respondents. A higher willingness to participate was found when a new drug had no side effects, no additional visit was required, balanced information was given, results were in the public domain, and the project was approved by a research ethics committee. In contrast, destruction of blood samples at the end of the project, use of placebo controls, and random allocation to study arms were associated with a lower likelihood of participation. The origin of funds, financial reward, the need to complete a questionnaire, and clinical vs. economic purpose of the study did not influence willingness to participate. CONCLUSION: Patients valued safety, convenience, oversight, and open communication in research. However, they were put off by some aspects that are valued by health care professionals. Educating the public about research methods may improve participation.
RCT Entities:
OBJECTIVE: To identify characteristics of clinical research projects that influence patients' willingness to participate in research. STUDY DESIGN AND SETTING: We surveyed all patients discharged during 1 month from a Swiss public teaching hospital. We described four hypothetical studies and asked patients whether they would agree to participate. We randomly manipulated three study attributes in each vignette, using a factorial design. RESULTS: All studies were not equally acceptable to the 1,277 respondents. A higher willingness to participate was found when a new drug had no side effects, no additional visit was required, balanced information was given, results were in the public domain, and the project was approved by a research ethics committee. In contrast, destruction of blood samples at the end of the project, use of placebo controls, and random allocation to study arms were associated with a lower likelihood of participation. The origin of funds, financial reward, the need to complete a questionnaire, and clinical vs. economic purpose of the study did not influence willingness to participate. CONCLUSION:Patients valued safety, convenience, oversight, and open communication in research. However, they were put off by some aspects that are valued by health care professionals. Educating the public about research methods may improve participation.
Authors: Ricki Carroll; Jules Antigua; Darren Taichman; Harold Palevsky; Paul Forfia; Steven Kawut; Scott D Halpern Journal: Clin Trials Date: 2012-03-02 Impact factor: 2.486
Authors: Patricia Schneider; Victoria Giglio; Dana Ghanem; David Wilson; Robert Turcotte; Marc Isler; Sophie Mottard; Benjamin Miller; James Hayden; Yee-Cheen Doung; Kenneth Gundle; R Lor Randall; Kevin Jones; Roberto Vélez; Michelle Ghert Journal: BMJ Open Date: 2021-02-26 Impact factor: 2.692
Authors: Paul Hilton; Brian S Buckley; Elaine McColl; Denise Howel; Douglas G Tincello; Catherine Brennand Journal: Trials Date: 2016-10-26 Impact factor: 2.279
Authors: Stéphane Cullati; Delphine S Courvoisier; Angèle Gayet-Ageron; Guy Haller; Olivier Irion; Thomas Agoritsas; Sandrine Rudaz; Thomas V Perneger Journal: BMC Med Res Methodol Date: 2016-05-04 Impact factor: 4.615